NGL Fine-Chem growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+36.1%+21.7%
EBITDA+114.7%+28.4%
Net Income+128.0%+32.9%
EPS (adj.)+128.0%+32.9%
Total Assets+25.9%+23.9%
Total Equity+16.6%+13.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,613 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+36.1+21.7
EBITDA+114.7+28.4
Net Income+128.0+32.9
EPS (adj.)+128.0+32.9
Total Assets+25.9+23.9
Total Equity+16.6+13.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.